The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...
The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...
Approval for the technology, which integrates with a smartphone, came sooner than company officials expected. A fully mobile continuous glucose monitoring (CGM) system, which features wireless ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the Food and Drug Administration (FDA) ...
Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...
For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...
FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...
A new diabetes device may make tracking blood sugars and taking medication easier. The U.S. Food and Drug Administration said Tuesday that the Dexcom G5 continuous glucose monitoring system (CGM) can ...
It’s a pretty good day for San Diego-based Dexcom. The company announced that it won CE Mark approval for its G5 continuous glucose monitor in the European Union. This means the device will be ...
The Food and Drug Administration (FDA) has expanded the use of Dexcom's G5 Mobile Continuous Glucose Monitoring (CGM) System to allow for replacement of blood glucose testing for diabetes treatment ...
Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the U.S. Food and Drug Administration (FDA) has approved its G5 Mobile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results